233 related articles for article (PubMed ID: 16309423)
21. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Pontani D; Washton H; Bouchillon S; Johnson J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
[TBL] [Abstract][Full Text] [Related]
22.
Flamm RK; Rhomberg PR; Sader HS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971877
[TBL] [Abstract][Full Text] [Related]
23. [Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].
Okubo T; Iyobe S; Fujiki Y; Sagai H
Jpn J Antibiot; 2003 Jun; 56(3):163-70. PubMed ID: 12942787
[TBL] [Abstract][Full Text] [Related]
24. Impact of carbon dioxide on the susceptibility of key respiratory tract pathogens to telithromycin and azithromycin.
Bouchillon SK; Johnson JL; Hoban DJ; Stevens TM; Johnson BM
J Antimicrob Chemother; 2005 Jul; 56(1):224-7. PubMed ID: 15890718
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
[TBL] [Abstract][Full Text] [Related]
26. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
Reinert RR; Rodloff AC; Halle E; Baer W; Beyreiss B; Seifert H; Wichelhaus TA; Maass M; Mehl M
Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
[TBL] [Abstract][Full Text] [Related]
27. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
28. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
Blondeau JM; Suter M; Borsos S
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
[TBL] [Abstract][Full Text] [Related]
29. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
[TBL] [Abstract][Full Text] [Related]
30. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
[TBL] [Abstract][Full Text] [Related]
31. Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin.
Fuchs PC; Barry AL; Brown SD
J Clin Microbiol; 2001 Jan; 39(1):43-6. PubMed ID: 11136745
[TBL] [Abstract][Full Text] [Related]
32. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
Mazzariol A; Koncan R; Vitali LA; Cornaglia G
J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
[TBL] [Abstract][Full Text] [Related]
33. In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.
Sato T; Tateda K; Kimura S; Iwata M; Ishii Y; Yamaguchi K
Antimicrob Agents Chemother; 2011 Apr; 55(4):1588-93. PubMed ID: 21220534
[TBL] [Abstract][Full Text] [Related]
34. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey.
Gonullu N; Catal F; Kucukbasmaci O; Ozdemir S; Torun MM; Berkiten R
Chemotherapy; 2009; 55(3):161-7. PubMed ID: 19390189
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
[TBL] [Abstract][Full Text] [Related]
36. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
37. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan.
Lau YJ; Hsueh PR; Liu YC; Shyr JM; Huang WK; Teng LJ; Liu CY; Luh KT
Microb Drug Resist; 2006; 12(2):130-5. PubMed ID: 16922631
[TBL] [Abstract][Full Text] [Related]
38. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
39. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 1997 Oct; 16(10):767-9. PubMed ID: 9405952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
